Portfolio
Portfolio

Fovea

Developing and commercializing drugs for the treatment of ocular diseases.

Developing and commercializing drugs for the treatment of ocular diseases, with a special focus on retinal pathologies. Fovea has multiple clinical programs ongoing in retinal degeneration, macular edema, glaucoma, and inflammation.

Fovea was acquired by Sanofi-aventis in 2009 for up to EUR 390 million.

  • Industry Biotech
  • History M&A